1 Global state: 1. No clinically significant response (as defined by the original studies) | 80 | | Risk Ratio (M-H, Random, 95% CI) | Subtotals only |

1.1 by up to 12 weeks -- short term | 80 | 6381 | Risk Ratio (M-H, Random, 95% CI) | 1.08 [0.96, 1.21] |

2 Global state: 2. Average endpoint total score(short term, up to 12 weeks, CGI, high=poor) | 2 | 196 | Mean Difference (IV, Random, 95% CI) | 0.35 [0.09, 0.61] |

3 Global state: 3. Average CGI subscale scores (short term, up to 12 weeks, high=poor) | 1 | 240 | Mean Difference (IV, Random, 95% CI) | 0.44 [0.22, 0.66] |

3.1 CGI-EI | 1 | 120 | Mean Difference (IV, Random, 95% CI) | 0.5 [0.14, 0.86] |

3.2 CGI-SI | 1 | 120 | Mean Difference (IV, Random, 95% CI) | 0.40 [0.12, 0.68] |

4 Global state: 4. average endpoint data of various scales (high=poor, data skewed) | | | Other data | No numeric data |

4.1 CGI-GI | | | Other data | No numeric data |

4.2 CGI-SI | | | Other data | No numeric data |

4.3 CGI | | | Other data | No numeric data |

5 Mental state: 1. Specific - binary outcomes (short term, up to 12 weeks) | 34 | | Risk Ratio (M-H, Random, 95% CI) | Subtotals only |

5.1 anxiety | 9 | 744 | Risk Ratio (M-H, Random, 95% CI) | 1.81 [1.12, 2.94] |

5.2 agitation/excitement | 26 | 2038 | Risk Ratio (M-H, Random, 95% CI) | 1.26 [0.86, 1.84] |

5.3 irritability | 1 | 100 | Risk Ratio (M-H, Random, 95% CI) | 1.0 [0.06, 15.55] |

6 Mental state: 2. Average endpoint scale score | 82 | | Mean Difference (IV, Random, 95% CI) | Subtotals only |

6.1 BPRS (short term, up to 12 weeks, high=poor) | 5 | 570 | Mean Difference (IV, Random, 95% CI) | -1.33 [-2.24, -0.42] |

6.2 PANSS (short term, up to 12 weeks, high=poor) | 77 | 5733 | Mean Difference (IV, Random, 95% CI) | -0.80 [-1.58, -0.02] |

6.3 PANSS (medium term, 12 to 24 weeks, high=poor) | 1 | 50 | Mean Difference (IV, Random, 95% CI) | -0.15 [-8.03, 7.73] |

6.4 SANS (medium term, 12 to 24 weeks, high=poor) | 1 | 50 | Mean Difference (IV, Random, 95% CI) | -0.55 [-3.72, 2.62] |

7 Mental state: 3. Specific - average endpoint positive score (PANSS, high=poor) | 40 | 3205 | Mean Difference (IV, Random, 95% CI) | 0.02 [-0.37, 0.41] |

7.1 short term (up to 12 weeks) | 39 | 3155 | Mean Difference (IV, Random, 95% CI) | 0.03 [-0.38, 0.43] |

7.2 medium term (12-26 weeks) | 1 | 50 | Mean Difference (IV, Random, 95% CI) | -0.21 [-2.38, 1.96] |

8 Mental state: 4. Specific - average endpoint negative score (PANSS, high=poor) | 37 | | Mean Difference (IV, Random, 95% CI) | Subtotals only |

8.1 short term (up to 12 weeks) | 37 | 2976 | Mean Difference (IV, Random, 95% CI) | -0.64 [-1.04, -0.25] |

9 Mental state: 5. Specific - average endpoint general psychopathological score (PANSS, high=poor ) | 58 | 4243 | Mean Difference (IV, Random, 95% CI) | -0.25 [-0.71, 0.20] |

9.1 by up to 12 weeks - short term | 57 | 4193 | Mean Difference (IV, Random, 95% CI) | -0.27 [-0.74, 0.19] |

9.2 12- 26 weeks - medium term | 1 | 50 | Mean Difference (IV, Random, 95% CI) | 1.52 [-2.66, 5.70] |

10 Mental state: 6. PANSS average score decreased rate (short term, up to 12 weeks, low=poor) | 5 | | Mean Difference (IV, Random, 95% CI) | Subtotals only |

10.1 total scale score decreased rate | 3 | 219 | Mean Difference (IV, Random, 95% CI) | 3.06 [0.24, 5.87] |

10.2 negative symptom subscale score decreased rate | 3 | 216 | Mean Difference (IV, Random, 95% CI) | -0.02 [-0.11, 0.08] |

10.3 positive symptom subscale score decreased rate | 3 | 216 | Mean Difference (IV, Random, 95% CI) | -0.01 [-0.10, 0.08] |

10.4 general pathology subscale score decreased rate | 1 | 50 | Mean Difference (IV, Random, 95% CI) | 2.38 [-0.33, 5.09] |

11 Mental state: 7. BPRS total score decreased rate (short term, up to 12 weeks, high=poor) | 2 | 132 | Mean Difference (IV, Random, 95% CI) | -2.97 [-6.61, 0.67] |

12 Mental state: 8. General - average total score (PANSS, high=poor) | 2 | | Mean Difference (IV, Random, 95% CI) | Subtotals only |

12.1 up to 12 weeks (short-term) | 2 | 372 | Mean Difference (IV, Random, 95% CI) | 1.5 [-2.96, 5.96] |

13 Mental state: 9. average scores of various scale (high=poor, skewed data) | | | Other data | No numeric data |

13.1 SANS endpoint scale score | | | Other data | No numeric data |

13.2 PANSS general pathology subscale score | | | Other data | No numeric data |

13.3 PANSS negative symptom subscale score | | | Other data | No numeric data |

13.4 PANSS positive symptom subscale score | | | Other data | No numeric data |

14 Leaving the study early | 17 | | Risk Ratio (M-H, Random, 95% CI) | Subtotals only |

14.1 Any reason | 12 | 1239 | Risk Ratio (M-H, Random, 95% CI) | 1.02 [0.79, 1.32] |

14.2 Progressive disease | 2 | 188 | Risk Ratio (M-H, Random, 95% CI) | 0.86 [0.14, 5.09] |

14.3 Not insisting follow up | 2 | 146 | Risk Ratio (M-H, Random, 95% CI) | 1.48 [0.49, 4.44] |

14.4 Termination treatment early | 1 | 100 | Risk Ratio (M-H, Random, 95% CI) | 3.0 [0.13, 71.92] |

14.5 Violation of study scheme | 2 | 152 | Risk Ratio (M-H, Random, 95% CI) | 1.32 [0.30, 5.83] |

14.6 Incomplete data | 1 | 180 | Risk Ratio (M-H, Random, 95% CI) | 5.0 [0.24, 102.71] |

14.7 Adverse effect | 9 | 1272 | Risk Ratio (M-H, Random, 95% CI) | 1.15 [0.64, 2.06] |

14.8 Economic issue | 2 | 160 | Risk Ratio (M-H, Random, 95% CI) | 1.02 [0.11, 9.60] |

14.9 No effect | 5 | 681 | Risk Ratio (M-H, Random, 95% CI) | 0.99 [0.49, 2.01] |

15 Adverse effects: 1. At least one adverse effect, non-specific | 51 | | Risk Ratio (M-H, Random, 95% CI) | Subtotals only |

15.1 non-specific | 28 | 2361 | Risk Ratio (M-H, Random, 95% CI) | 0.81 [0.73, 0.91] |

15.2 liver function abnormal | 29 | 2300 | Risk Ratio (M-H, Random, 95% CI) | 0.63 [0.46, 0.86] |

15.3 hyper-salivation | 7 | 554 | Risk Ratio (M-H, Random, 95% CI) | 0.63 [0.22, 1.80] |

15.4 myalgia/ostealgia | 2 | 100 | Risk Ratio (M-H, Random, 95% CI) | 1.95 [0.51, 7.46] |

15.5 renal function abnormal | 1 | 100 | Risk Ratio (M-H, Random, 95% CI) | 0.0 [0.0, 0.0] |

15.6 sexual desire change | 8 | 614 | Risk Ratio (M-H, Random, 95% CI) | 0.11 [0.04, 0.30] |

15.7 sweating- increase | 4 | 278 | Risk Ratio (M-H, Random, 95% CI) | 0.65 [0.16, 2.59] |

15.8 stuffy nose | 2 | 165 | Risk Ratio (M-H, Random, 95% CI) | 3.90 [0.44, 34.47] |

16 Adverse effects: 2a.Cardiac effects (short term, up to 12 weeks) | 61 | | Risk Ratio (M-H, Random, 95% CI) | Subtotals only |

16.1 abnormal ECG | 12 | 1032 | Risk Ratio (M-H, Random, 95% CI) | 0.66 [0.41, 1.05] |

16.2 blood pressure decline or rise | 5 | 363 | Risk Ratio (M-H, Random, 95% CI) | 1.54 [0.46, 5.15] |

16.3 blood pressure- increase | 1 | 80 | Risk Ratio (M-H, Random, 95% CI) | 1.0 [0.06, 15.44] |

16.4 blood pressure- decrease | 6 | 504 | Risk Ratio (M-H, Random, 95% CI) | 1.15 [0.45, 2.90] |

16.5 EEG abnormal | 1 | 120 | Risk Ratio (M-H, Random, 95% CI) | 0.67 [0.12, 3.85] |

16.6 postural hypotension | 6 | 399 | Risk Ratio (M-H, Random, 95% CI) | 0.94 [0.46, 1.93] |

16.7 QTc prolongation | 5 | 649 | Risk Ratio (M-H, Random, 95% CI) | 0.37 [0.13, 1.09] |

16.8 tachycardia | 49 | 3835 | Risk Ratio (M-H, Random, 95% CI) | 0.76 [0.61, 0.96] |

17 Adverse effects: 2b. Cardiac - QTc change from baseline (in ms) | 2 | 383 | Mean Difference (IV, Random, 95% CI) | -7.19 [-12.19, -2.19] |

18 Adverse effects: 3. Central / peripheral nervous system (short term, up to 12 weeks) | 63 | | Risk Ratio (M-H, Random, 95% CI) | Subtotals only |

18.1 acute onset of schizophrenia | 2 | 120 | Risk Ratio (M-H, Random, 95% CI) | 1.33 [0.49, 3.64] |

18.2 dizziness | 23 | 1896 | Risk Ratio (M-H, Random, 95% CI) | 1.06 [0.72, 1.54] |

18.3 blurred vision | 39 | 3272 | Risk Ratio (M-H, Random, 95% CI) | 0.96 [0.70, 1.32] |

18.4 fatigue | 5 | 369 | Risk Ratio (M-H, Random, 95% CI) | 0.62 [0.29, 1.35] |

18.5 headache | 20 | 1505 | Risk Ratio (M-H, Random, 95% CI) | 1.91 [1.31, 2.78] |

18.6 headache/dizziness | 20 | 1486 | Risk Ratio (M-H, Random, 95% CI) | 1.29 [0.93, 1.79] |

18.7 insomnia | 54 | 4209 | Risk Ratio (M-H, Random, 95% CI) | 1.17 [0.98, 1.39] |

18.8 memory decrease | 1 | 60 | Risk Ratio (M-H, Random, 95% CI) | 0.22 [0.05, 0.94] |

18.9 sedation | 2 | 170 | Risk Ratio (M-H, Random, 95% CI) | 0.20 [0.04, 1.18] |

18.10 sleep disorder | 2 | 152 | Risk Ratio (M-H, Random, 95% CI) | 0.85 [0.39, 1.86] |

18.11 somnolence | 35 | 2779 | Risk Ratio (M-H, Random, 95% CI) | 0.95 [0.74, 1.22] |

19 Adverse effects: 3a. Endocrine - Prolactin - average change (ng/ml) | 2 | 383 | Mean Difference (IV, Random, 95% CI) | -54.71 [-60.06, -49.36] |

20 Adverse effects: 3b. Endocrine - Prolactin-associated | 1 | | Risk Ratio (M-H, Random, 95% CI) | Subtotals only |

20.1 abnormally high prolactin value | 1 | 301 | Risk Ratio (M-H, Random, 95% CI) | 0.04 [0.02, 0.08] |

20.2 dysmenorrhoea | 1 | 91 | Risk Ratio (M-H, Random, 95% CI) | 3.17 [0.17, 59.43] |

21 Adverse effects: 4. Various extrapyramidal symptoms (short term, up to 12 weeks) | 64 | | Risk Ratio (M-H, Random, 95% CI) | Subtotals only |

21.1 akathisia | 42 | 3501 | Risk Ratio (M-H, Random, 95% CI) | 0.60 [0.48, 0.74] |

21.2 tremor | 36 | 2799 | Risk Ratio (M-H, Random, 95% CI) | 0.35 [0.27, 0.45] |

21.3 dystonia | 32 | 2640 | Risk Ratio (M-H, Random, 95% CI) | 0.35 [0.25, 0.49] |

21.4 parkinsonism | 1 | 301 | Risk Ratio (M-H, Random, 95% CI) | 7.39 [0.43, 128.08] |

21.5 use of antiparkinson medication | 1 | 83 | Risk Ratio (M-H, Random, 95% CI) | 0.59 [0.32, 1.12] |

21.6 extrapyramidal symptoms | 31 | 2605 | Risk Ratio (M-H, Random, 95% CI) | 0.39 [0.31, 0.50] |

21.7 torsion spasm | 3 | 200 | Risk Ratio (M-H, Random, 95% CI) | 0.52 [0.04, 7.18] |

21.8 tremor | 2 | 391 | Risk Ratio (M-H, Random, 95% CI) | 1.21 [0.07, 21.13] |

21.9 increase activities | 1 | 64 | Risk Ratio (M-H, Random, 95% CI) | 5.0 [0.25, 100.20] |

22 Adverse effects: 4b. Extrapyramidal - average score | 2 | | Mean Difference (IV, Random, 95% CI) | Subtotals only |

22.1 Abnormal Involuntary Movement Scale (high=poor) | 2 | 383 | Mean Difference (IV, Random, 95% CI) | -0.25 [-1.24, 0.75] |

22.2 Barnes Akathisia Scale (high=poor) | 2 | 383 | Mean Difference (IV, Random, 95% CI) | -0.11 [-0.49, 0.27] |

22.3 Simpson-Angus Scale (high=poor) | 2 | 383 | Mean Difference (IV, Random, 95% CI) | -0.70 [-2.22, 0.82] |

23 Adverse effects: 5. Gastrointestinal | 46 | | Risk Ratio (M-H, Random, 95% CI) | Subtotals only |

23.1 constipation | 27 | 2067 | Risk Ratio (M-H, Random, 95% CI) | 0.75 [0.52, 1.08] |

23.2 dry mouth | 33 | 2658 | Risk Ratio (M-H, Random, 95% CI) | 1.20 [0.86, 1.69] |

23.3 gastrointestinal reaction | 3 | 300 | Risk Ratio (M-H, Random, 95% CI) | 2.01 [0.76, 5.37] |

23.4 nausea / vomiting | 28 | 2180 | Risk Ratio (M-H, Random, 95% CI) | 1.84 [1.31, 2.56] |

24 Adverse effects: 6. Haematological | 8 | | Risk Ratio (M-H, Random, 95% CI) | Subtotals only |

24.1 blood routine abnormal | 6 | 515 | Risk Ratio (M-H, Random, 95% CI) | 0.45 [0.20, 1.02] |

24.2 leucopenia | 1 | 60 | Risk Ratio (M-H, Random, 95% CI) | 0.33 [0.01, 7.87] |

24.3 blood lipid abnormal | 1 | 80 | Risk Ratio (M-H, Random, 95% CI) | 2.0 [0.19, 21.18] |

25 Adverse effects: 7a. Metabolic - binary measures (short term, up to 12 weeks) | 62 | | Risk Ratio (M-H, Random, 95% CI) | Subtotals only |

25.1 appetite- decrease | 2 | 204 | Risk Ratio (M-H, Random, 95% CI) | 0.26 [0.07, 1.03] |

25.2 blood glucose- increase | 5 | 358 | Risk Ratio (M-H, Random, 95% CI) | 0.28 [0.09, 0.82] |

25.3 endocrine disorder | 9 | 642 | Risk Ratio (M-H, Random, 95% CI) | 0.07 [0.03, 0.17] |

25.4 lactation | 3 | 216 | Risk Ratio (M-H, Random, 95% CI) | 0.11 [0.02, 0.60] |

25.5 menstrual disorder/lactation | 29 | 2278 | Risk Ratio (M-H, Random, 95% CI) | 0.10 [0.06, 0.16] |

25.6 menstrual disorder or sexual function change | 1 | 68 | Risk Ratio (M-H, Random, 95% CI) | 0.07 [0.00, 1.12] |

25.7 menstrual disorder | 9 | 655 | Risk Ratio (M-H, Random, 95% CI) | 0.13 [0.06, 0.27] |

25.8 skin symptom | 9 | 778 | Risk Ratio (M-H, Random, 95% CI) | 0.32 [0.12, 0.86] |

25.9 PRL-increase | 3 | 184 | Risk Ratio (M-H, Random, 95% CI) | 0.07 [0.01, 0.38] |

25.10 obesity | 1 | 72 | Risk Ratio (M-H, Random, 95% CI) | 0.95 [0.14, 6.35] |

25.11 vaginal bleeding | 1 | 72 | Risk Ratio (M-H, Random, 95% CI) | 2.84 [0.12, 67.53] |

25.12 weight gain | 58 | 4623 | Risk Ratio (M-H, Random, 95% CI) | 0.22 [0.17, 0.29] |

25.13 weight loss | 1 | 101 | Risk Ratio (M-H, Random, 95% CI) | 2.94 [0.12, 70.56] |

26 Adverse effects: 7b. Metabolic - continuous measures (high=poor ) | 7 | | Mean Difference (IV, Random, 95% CI) | Subtotals only |

26.1 endpoint average weight (in kg) | 5 | 465 | Mean Difference (IV, Random, 95% CI) | -2.30 [-4.17, -0.44] |

26.2 weight change from baseline (in kg) | 1 | 100 | Mean Difference (IV, Random, 95% CI) | -1.50 [-1.84, -1.16] |

26.3 average endpoint BMI of male (in kg/m2) | 1 | 60 | Mean Difference (IV, Random, 95% CI) | -2.46 [-4.08, -0.84] |

26.4 average endpoint BMI of female (in kg/m2) | 2 | 124 | Mean Difference (IV, Random, 95% CI) | -1.47 [-3.55, 0.60] |

26.5 average endpoint blood glucose of female (in mmol/L) | 1 | 60 | Mean Difference (IV, Random, 95% CI) | 4.29 [3.97, 4.61] |

26.6 average endpoint blood glucose of male (in mmol/L) | 1 | 60 | Mean Difference (IV, Random, 95% CI) | 0.28 [-0.04, 0.60] |

26.7 average endpoint blood glucose FBG (in mg/dl) | 1 | 60 | Mean Difference (IV, Random, 95% CI) | -0.08 [-0.37, 0.21] |

26.8 average endpoint cholesterol - TC of female (in mmol/L) | 1 | 60 | Mean Difference (IV, Random, 95% CI) | -0.51 [-0.96, -0.06] |

26.9 average endpoint cholesterol - TC of male (in mmol/L) | 1 | 60 | Mean Difference (IV, Random, 95% CI) | -0.48 [-0.96, -0.00] |

26.10 average endpoint cholesterol - TC level (in mmol/L) | 2 | 240 | Mean Difference (IV, Random, 95% CI) | -0.02 [-0.19, 0.14] |

26.11 average endpoint cholesterol-TG level (in mmol/L) | 1 | 60 | Mean Difference (IV, Random, 95% CI) | -0.07 [-0.21, 0.07] |

26.12 average endpoint cholesterol - LDL level (in mmol/L) | 2 | 240 | Mean Difference (IV, Random, 95% CI) | 0.07 [-0.11, 0.26] |

26.13 average endpoint waistline (in cm) | 1 | 180 | Mean Difference (IV, Random, 95% CI) | -3.30 [-5.47, -1.13] |

27 Adverse effect : 7c. Metabolic - continuous measures | 4 | 789 | Mean Difference (IV, Random, 95% CI) | -0.01 [-0.22, 0.21] |

27.1 average endpoint cholesterol- HDL level (in mmol/L) | 2 | 240 | Mean Difference (IV, Random, 95% CI) | 0.06 [-0.03, 0.14] |

27.2 cholesterol - change from baseline (in mg/dl) | 1 | 83 | Mean Difference (IV, Random, 95% CI) | -22.3 [-39.69, -4.91] |

27.3 glucose - change from baseline (in mg/dl) | 1 | 83 | Mean Difference (IV, Random, 95% CI) | 6.8 [-6.10, 19.70] |

27.4 weight gain - change from baseline (in kg) | 2 | 383 | Mean Difference (IV, Random, 95% CI) | -0.54 [-1.24, 0.15] |

28 Adverse effect: 8. required additional drug combination | 2 | | Risk Ratio (M-H, Random, 95% CI) | Subtotals only |

28.1 benzodiazepines | 2 | 138 | Risk Ratio (M-H, Random, 95% CI) | 1.07 [0.73, 1.58] |

28.2 benzhexol | 1 | 69 | Risk Ratio (M-H, Random, 95% CI) | 0.34 [0.12, 0.93] |

28.3 benzhexol/propranolol | 1 | 69 | Risk Ratio (M-H, Random, 95% CI) | 1.11 [0.45, 2.72] |

29 Adverse effects: 9. TESS score (short term, up to 12 weeks, high=poor) | 4 | 250 | Mean Difference (IV, Random, 95% CI) | -1.34 [-2.30, -0.39] |

30 Adverse effects: 10. TESS score (short term, up to 12 weeks, high=poor, data skewed) | | | Other data | No numeric data |

31 Adverse effects: 11. weight gain (in KG, high=poor, data skewed) | | | Other data | No numeric data |

32 Cognitive functioning: 1. Specific - average endpoint total score | 1 | | Mean Difference (IV, Random, 95% CI) | Subtotals only |

32.1 (short term, up to 12 weeks, WMS, low= poor) | 1 | 72 | Mean Difference (IV, Random, 95% CI) | -1.56 [-7.95, 4.83] |

32.2 (short term, up to 12 weeks, WAIS-RC, low=poor) | 1 | 72 | Mean Difference (IV, Random, 95% CI) | -1.57 [-8.92, 5.78] |

33 Cost effectiveness analysis (high=poor, data skewed) | | | Other data | No numeric data |

33.1 Cost of hospitalisation (in RMB) | | | Other data | No numeric data |

33.2 Cost of drug (in RMB) | | | Other data | No numeric data |

33.3 Length of hospitalisation (day) | | | Other data | No numeric data |